Viral Kansara

Discovery & Development US 2026 puts your brand in front of thousands of biopharma decision-makers. 52% from pharma and biotech, 60% actively budgeted for new solutions. Through immersive sponsorship formats, guaranteed 1:1 meetings with pre-qualified buyers, audience engagement data, and tailored media coverage, it's a platform built to accelerate your pipeline conversations and visibility in one place.

By Viral Kansara, Ph.D., chief scientific advisor, NeuParadigm Bio Let me be direct: AI (artificial intelligence) is not going to replace the biologist, the pharmacologist, or the translational scientist. What it is doing right now is changing the quality of decisions we make before we commit tens of millions of dollars to a clinical hypothesis. That distinction matters enormously, and it gets lost in most conversations about AI in drug discovery. Retinal drug discovery has always been hard.